Introduction
============

Male breast cancer (MBC) represents 1% of all breast cancer cases in the United States, with 2,240 new cases and 410 deaths expected by 2013 [@B1], [@B2]. Analysis of the Surveillance, Epidemiology and End Results (SEER) data from 1973-2008 has shown the overall incidence of MBC is 1.5 cases per 100,000 males [@B3] with White males being more frequently affected than other ethnic groups. MBC can be hereditary or sporadic. Genetic risk factors for MBC include *BRCA2* carriers [@B4] and patients with Cowden and Klinefelter syndromes. Recently, the MBC Pooling Project from the National Cancer Institute has shown that there may be a significant risk for MBC associated with increased body mass index and gynecomastia after combination of data from case-control and large cohort studies [@B5].

MBC presents at a later onset compared to breast cancer in women (65-69 vs. 60-64 years), aspect that contributes to its unfavorable overall prognosis, often being discovered in advanced stages with lymph node metastases [@B6], [@B7]. In the SEER analysis, 12% of men were diagnosed with breast carcinoma before the age of 50 whereas 40% were diagnosed after age 70 [@B3].

Clinically, MBC presents as a palpable mass with or without nipple involvement, manifested as retraction, fixation, bloody discharge or erythematous scaling. MBC shares some morphological characteristics with female breast cancer (FBC). The most common histological type is ductal carcinoma whereas lobular carcinoma is extremely rare. Papillary carcinomas are more common than in its female counterpart [@B8]. MBC is characteristically positive for estrogen and progesterone receptors and negative for Her2. Differential diagnosis includes gynecomastia and metastatic carcinoma or melanoma [@B8].

At the molecular level, MBC is a heterogeneous disease that differs from FBC. By gene expression profiling Johansson *et al*. [@B9] have identified two different subgroups of MBC -designated luminal M1 and luminal M2- which appear to occur only in males and have a unique biology. Although both subgroups show expression of estrogen receptor, luminal M1 tumors are associated with aggressive behavior and worse prognosis, whereas luminal M2 tumors may behave less aggressive and contain high levels of immune response related genes and genes associated with estrogen receptor signaling [@B9].

However, because of the rareness of MBC and the lack of large series studies, the current knowledge about its biology and treatment is still limited and based on what is known about its female presentation. The majority of patients diagnosed with loco-regional MBC undergo total mastectomy. However, breast conservative surgery seems to have equivalent outcomes and less secondary effects than radical surgery in this set of patients [@B3], [@B10].

Mature microRNAs (miRNAs) are small (approximately 18-25 nucleotides long) non-protein coding RNAs. miRNAs modulate gene expression by acting post-transcriptionally, through either messenger RNA degradation or translation inhibition [@B11]. Since the discovery of miRNAs [@B12], several studies have demonstrated their involvement in carcinogenesis by promoting expression of proto-oncogenes or by inhibiting the expression of tumor suppressor genes [@B13]. miRNA expression profile platforms have been especially used to characterize several types of cancers, helping to understand tumor development and progression [@B14], [@B15]. Numerous studies show that different solid tumors in fact display a cancer type-specific deregulation of miRNAs [@B16]-[@B18]. One of the first studies demonstrating miRNA deregulation through a comparison of cancerous and normal mammary tissues by miRNA microarray identified a panel of 29 miRNAs modulated specifically in breast cancer samples from female patients [@B16]. However, only few studies have been reported regarding miRNA expression profiling in MBC [@B13], [@B19], [@B20], [@B21], all showing different miRNA signatures associated with breast tumors in males; therefore, the current knowledge about the involvement of miRNAs in MBC development is scarce and not conclusive.

To further elucidate the possible differences between MBC and previously reported FBC miRNA profiles, we performed a comprehensive profiling of 800 miRNAs in 9 MBC samples and in normal epithelial cells from 3 of the same MBC cases.

Material and Methods
====================

Patient Samples
---------------

Forty-two cases of MBC were retrieved from the surgical archives of the Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA after IRB approval. Hematoxylin and eosin (H&E) stained slides were reviewed to confirm the diagnosis and their clinicopathological features were reviewed, including tumor size, lymph node metastasis and status of estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), Her-2 and Ki-67. For the profiling study of 800 microRNAs, 9 tumor and 3 normal epithelium samples were available. For a detailed description of all MBC cases included in this study see Table [1](#T1){ref-type="table"}.

RNA Isolation
-------------

Isolation of total RNA from formalin-fixed paraffin embedded (FFPE) specimens was performed as described previously Further support the hypothesis that MBC have a different microRNA expression profile in comparison with normal mammary tissue and with that reported for FBC[@B22]. Briefly, ten micron formalin-fixed paraffin-embedded (FFPE) tissue sections were deparaffinized in three consecutive Xylene baths, rehydrated in graded ethanol and manually microdissected under light microscope to obtain separate amounts of tumor and normal breast tissue. RNA isolation was performed using the RecoverAll™ Total Nucleic Acid Isolations Kit (Ambion^®^ by Life Technoligies, Foster City, CA, USA). The concentration of all RNA samples was quantified using NanoDrop 2000 (Thermo Scientific, Wilmington, DE, USA). RNA concentration of samples used for profiling was normalized at 33 ng/µl following the recommendations from NanoString Technologies.

MicroRNA profiling using NanoString nCounter miRNA assay
--------------------------------------------------------

Total RNA samples were analyzed according to manufacturer\'s instructions for the nCounter Human miRNA Expression Assay kit (NanoString Technologies^®^, Seattle, WA). Briefly, 100 ng of each total RNA sample was used as input into the nCounter Human miRNA sample preparation. Hybridization was conducted for 16 h at 65°C. Subsequently, probes were purified and counted on the nCounter Prep Station. Each sample was scanned for 600 FOV (fields of view) on the nCounter Digital Analyzer. Data was extracted using the nCounter RCC Collector.

NanoString nCounter miRNA data analysis
---------------------------------------

For platform validation using synthetic oligonucleotides, NanoString nCounter miRNA raw data was normalized for lane-to-lane variation with a dilution series of six spike-in positive controls. The sum of the six positive controls for a given lane was divided by the average sum across lanes to yield a normalization factor, which was then multiplied by the raw counts in each lane to give normalized values. For each sample, the mean plus 2 times the standard deviation of the 8 negative controls was subtracted from each miRNA count in that sample. Only miRNAs with non-negative counts across all samples were retained for downstream analysis. The relative miRNA levels were indicated as median fold changes and a cutoff of 2 fold-change (up or down) was used.

Quantitative real-time PCR
--------------------------

Detection and quantification of selected mature miRNAs was carried out using Reverse transcription quantitative real-time PCR (RT-qPCR) and the TaqMan miRNA Assay (Assay ID: 000387 Applied Biosystems, Foster City, CA) according to the manufacturer\'s protocol. RNA samples were measured in triplicates. Preparation of cDNA was performed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). Reverse transcription reactions were performed in a GeneAmp PCR system 9700 thermal cycler (Applied Biosystems) with samples incubated at 16°C for 30 minutes, 42°C for 30 minutes and 85°C for 5 minutes. An RT-negative control was included in each batch of reactions. Each reaction consisted of 15 μl final volume, with 10 ng of total RNA including miRNAs. The qPCR reaction mix consisted of 20 μl final volume with RT product, TaqMan 2X Universal PCR Master Mix II and the appropriate 20X MicroRNA Assay Mix containing the probe for the miRNA of interest. PCR reactions were initially incubated for 10 minutes at 95°C, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Inter-assay control and calibrator were included in each 96-well plate. All TaqMan assays (See Table [2](#T2){ref-type="table"}) were run in triplicate using an AB StepOnePlus RealTime PCR System. Ct values were calculated with the StepOne Software v2.2.2 using automatic baseline settings. RNU6B (assay ID: 001093) was used as endogenous control for normalizing the expression level of selected miRNAs. The mean of Ct values was subtracted from the corresponding Ct value for the selected miRNAs resulting in the ΔCt value which was used for relative quantification of miRNA expression (ΔΔCt method). Changes is expression levels in tumor samples are shown as relative (fold change) to normal tissue.

Statistical Analysis
--------------------

Welch based t-tests were carried out using MultiExperiment Viewer software (MeV version 4.8, <http://www.tm4.org>) to compare the two groups (normal vs. tumor) and to evaluate differences between miRNA expression and patient characteristics. Only mature miRNAs that showed at least a 2-fold change in expression are reported. Regarding RT-qPCR data, results are presented as the mean values and standard error of the mean. *P*-values were calculated for each miRNA between the normal and tumor samples using the biological replicates and genes were considered statistically significant if their *P* value was less than 0.05.

Results
=======

Characterization of the studied population
------------------------------------------

The clinicopathologic characteristics of the 42 cases included in the present study are shown in Table [1](#T1){ref-type="table"}. Patient\'s age range was 36-85 (mean 63 ± 12.9). Majority of the tumors were moderate to high grade and ranged between 0.2 and 7 cm in size. Histologically, 76% of the tumors were invasive ductal carcinomas (four papillary type); eight cases were DCIS, 4 of which were papillary; and 1 was mucinous. Thirty-six percent were grade 2 and 26.2% grade 3. Lymph node status was known in 71% of the cases, of these, 70% had lymph node metastasis. Prognostic factors were known in 28 cases, 23 (82%) were ER+/PR+, 2 (7.1%) ER+/PR-, 1 (3.5%) ER-/PR+, Her2 amplification was seen in 6 cases (21%) and 2 cases were triple negative (7.1%). AR was heterogeneous and was strongly + in DCIS.

Human male breast cancer tissue presents a different MicroRNA expression profile compare to its normal counterpart and to female breast cancer
----------------------------------------------------------------------------------------------------------------------------------------------

To determine if MBC possesses a tumor-specific pattern of miRNAs expression, a panel of 800 miRNAs was analyzed in 9 MBC samples and compared against the expression of the same miRNAs on 3 normal epithelial components obtained from the same group of patients.

A T-test based analysis was performed comparing the normal epithelium group versus the tumor group within MBC samples. Unsupervised hierarchical clustering of the miRNA expression data showed clear separation between normal and tumor mammary tissue, indicating a clear cancer-specific expression patter of a number of miRNAs in our MBC samples (Figure [1](#F1){ref-type="fig"}). In total, 49 miRNAs were up-regulated ranging from 2.05 fold up 6.57 fold change while 25 miRNAs showed to be down-regulated ranging from -2.08 fold to -18.86 fold change (Table [2](#T2){ref-type="table"}). Some of the miRNA genes showed no statistically significant difference, which not necessarily means that the difference is not biologically significant. It is possible that these results respond to the fact that a small sample was used or the data were quite variable.

Among the up-regulated miRNAs, hsa-miR-200a-3p, hsa-miR-30a-5p, hsa-miR-29b-3p, hsa-miR-222-3p, hsa-miR-141-3p, hsa-miR-342-3p, hsa-miR-135b-5p, hsa-miR-29c-3p and hsa-miR-183-5p were the most prominently up-regulated (p\<0.05). In particular, hsa-miR-200a-3p and hsa-miR-183-5p have been reported as over-expressed in MBC[@B19] as well as in its female counterpart[@B23], [@B24] while hsa-miR-30a-5p, hsa-miR-29b-3p, hsa-miR-222-3p, hsa-miR-141-3p, hsa-miR-342-3p, hsa-miR-135b-5p and hsa-miR-29c-3p have no reports to the present in MBC. On the other hand, hsa-miR-125b-5p, hsa-miR-4516, hsa-miR-143-3p, hsa-miR-214-3p, hsa-miR-575, hsa-miR-548ai, hsa-miR-203, hsa-miR-630, hsa-miR-145-5p and hsa-miR-1253 were the most down-regulated. From these, hsa-miR-145-5p has been reported as significantly down-regulated in both male and female breast cancer [@B19], [@B25].

The miRNA profile found in our study showed some differences from previously published miRNA profiles in FBC (Table [2](#T2){ref-type="table"}). From the 74 miRNAs found to be deregulated in MBC, 37 (50%) have shown the same expression pattern in FBC and another 30% (22 miRNAs), to our knowledge, have no reports in this regard in FMC. On the other hand, and important 20% (15 miRNAs) showed an opposite expression pattern between male and female breast tumors. For instance, expression of hsa-miR-296-5p have shown to be down-regulated in FBC[@B26], while in the present study showed to be up-regulated more than two fold in the male tumors. Similarly, hsa-miR-135b-5p, hsa-miR-1180, hsa-miR-503, hsa-miR-9-5p, hsa-miR-34a-5p, hsa-miR-362-5p, hsa-181c-5p, hsa-miR-25-3p, hsa-miR-125a, hsa-miR-424-5p, hsa-miR-425-5p, and hsa-miR-194-5p showed to be significantly up-regulated in our cohort of male tumors while in FBC these miRNAs have shown to be down-regulated[@B23], [@B27]-[@B29]. Among the most down-regulated miRNAs found in the present study (more than 2 fold decrease in expression), hsa-miR-155-5p and hsa-miR-203 have shown to be up-regulated in female breast tumors [@B25], [@B30].

Validation of differentially expressed microRNAs using Quantitative real-time PCR
---------------------------------------------------------------------------------

In order to validate the most deregulated miRNA we performed RT-qPCR. We tested the differential expression of several miRNAs including hsa-miR-200a, hsa-miR-30a, hsa-miR-183, as they were the most up-regulated, and hsa-miR-125b, hsa-miR-145 and hsa-miR-1253, as they behaved as the most down-regulated. For this, 16 MBC cases (profiling cohort, n~tumor~=8 and n~normal~=4; independent cohort, n~tumor~=8 and n~normal~=3) were used. The quantitative real-time PCR data confirmed the results obtained by miRNA profiling analysis (Figures [2](#F2){ref-type="fig"}). As shown in Figure [2](#F2){ref-type="fig"}, miR-200a, miR-30a and miR-183 were over-expressed in cancer samples, whereas miR-125b, miR-145 and miR-1253 were under-expressed. The differential expression among tumor and normal samples for hsa-miR-183, hsa-miR-125b and hsa-miR-145 were statistically significant in both studied cohorts. The rest of the miRNAs either showed statistically significant difference only in one group (miR-30a) or only a trend in both cohorts (miR-200a and miR-1253).

Correlation between microRNA expression and clinicopathological features in patients with male breast cancer
------------------------------------------------------------------------------------------------------------

Using the expression profiling data, we also evaluated whether a correlation exists between various clinicopathological features associated with tumor specimens and the expression of the most deregulated miRNAs. We analyzed the group of MBC cases selected for expression profiling regarding tumor grade (moderate to high grade), degree of lymph nodes metastasis, tumor size and Ki-67 expression level. Whereas no statistically significant association were found between miRNA expression and degree of lymph nodes metastasis and Ki-67 expression levels (data not shown), a statistically significant association between tumor size and hsa-miR-125b and tumor grade and hsa-miR-200a and hsa-miR-30a, were noticed (*P* \< 0.05) (Table [3](#T3){ref-type="table"}).

Discussion
==========

In the present study we present a comprehensive profiling of 800 miRNA in MBC, which showed differences between miRNA expression of the breast cancer and their normal counterpart, suggesting a cancer-specific miRNA expression profile for MBC. Due to the low incidence of MBC and lack of large series studies, the current knowledge about its biology is limited. Most knowledge about genetic and molecular alterations has been extrapolated from FBC. Only few studies have analyzed the miRNA profiling in both female and male breast cancer [@B13], [@B19], [@B20], [@B21]. In fact, several of the most recent analyses on miRNAs and MBC analyzed cases of familiar MBC. When compared with previously reported profiling studies in FBC [@B23], [@B25], [@B28], some of the altered miRNAs found in this study had been also identified to be deregulated in the female group. Forty-nine miRNAs showed increased expressions while 25 miRNAs were found to be down-regulated in MBC tissue when compared with normal tissue. Particularly, hsa-miR-200a-3p, hsa-miR-30a-5p, hsa-miR-29b-3p, hsa-miR-222-3p, hsa-miR-141-3p, hsa-miR-342-3p, hsa-miR-135b-5p, hsa-miR-29c-3p, hsa-miR-183-5p were the most prominently up-regulated and hsa-miR-125b-5p, hsa-miR-4516, hsa-miR-143-3p, hsa-miR-214-3p, hsa-miR-575, hsa-miR-548ai, hsa-miR-203, hsa-miR-630, hsa-miR-145-5p and hsa-miR-1253 were the most down-regulated in MBC.

From this group of 19 most deregulated miRNAs, 12 have been reported to be differentially expressed in other tumors, including FBC (hsa-miR-200a-3p, hsa-miR-30a-5p, hsa-miR-29b-3p, hsa-miR-222-3p, hsa-miR-141-3p, hsa-miR-342-3p, hsa-miR-183-5p, hsa-miR-125b-5p, hsa-miR-214-3p, hsa-miR-575, hsa-miR-203 and hsa-miR-145-5p)[@B24], [@B25], [@B31]-[@B34] whereas the remaining 7 miRNAs had no previous reports in this regard.

Among the seventy-four miRNA that were found to be deregulated in MBC, 37 of them had been reported to show the same expression pattern in FBC (Table [2](#T2){ref-type="table"}). However, an important fraction (20%) showed opposite expression pattern between the two populations. Among these group, hsa-miR-222, hsa-miR-34a, hsa-miR-181c has been shown to be differentially expressed in tamoxifen-resistant and tamoxifen-sensitive breast cancer cell lines. The authors suggest that these miRNAs with opposite expression between the two cell lines may be involved in endocrine resistance [@B35]. The cell lines used in the mentioned study are well-known models of FBC, which emphasize the significance of our findings regarding differentially expressed miRNAs possibly implicated in resistance development. These findings highlight the relevance of considering the differences in miRNA expression patterns between male and female breast tumors when considering treatment options and overall disease management.

Among the several miRNAs we found to be deregulated in MBC and that had been suggested to be involved in the development and progression of cancer, hsa-miR-200a-3p and hsa-miR-183-5p have been reported as over-expressed and hsa-miR-145-5p as significantly down-regulated in both male and female breast cancer. It was recently reported that the hsa-miR-200a suppresses the epithelial-mesenchymal transition (EMT), the initiating step of metastasis, which has being supported by data suggesting that hsa-miR-200a, targeting of YAP1 (Yes-associated protein 1), suppresses the pro-apoptotic protein expression and allows the cells to evade anoikis [@B24]. Other studies have demonstrated that some miRNAs, including hsa-miR-141, hsa-miR-183, hsa-miR-200b/c and miR-21 may be implicated in the progression of the disease. We found that hsa-miR-183, hsa-miR-141 and hsa-miR-200b/c, that have been noted to increase during the Normal-atypical ductal hyperplasia (ADH) transition, and maintained their high expression profiles during later stages, were over-expressed in our cases suggesting tumor progression [@B23].

We found down-regulation of hsa-miR-145, a possible tumor suppressor miRNA which has been demonstrated in other cancers including FBC. Iorio et al. (2005) demonstrated that hsa-miR-145 is progressively down-regulated from normal breast to cancer with high proliferation index suggesting that deregulation of this miRNA may affect critical molecular events involved in tumor progression. Recent studies show that hsa-miR-145 is down-regulated in human cancer cell line MCF-7 and that when over-expressed by plasmid inhibits MCF-7 cell growth and induces apoptosis [@B27]. More recently, other study found that hsa-miR-145 exhibited a pro-apoptotic effect, which is dependent on TP53 activation, and that TP53 activation can, in turn, stimulate hsa-miR-145 expression, thus establishing a death promoting loop between miR-145 and TP53. It was also found that hsa-miR-145 can down-regulate ER-α protein expression. These findings support a view that hsa-miR-145 re-expression therapy could be mainly envisioned in the specific group of patients with ER-α-positive and/or TP53 wild-type tumors [@B36].

We also found hsa-miR-125b to be down-regulated in tumor samples. Previous studies demonstrate the involvement of miR-125b in the progression of breast cancer. Iorio *et al*. (2005) showed that breast cancer primary tumors and cell lines have decreased levels of miR-125b expression, suggesting that lack of this miRNA may impair differentiation capabilities of cancer cells [@B25]. Baffa *et al.* (2009), seeking a specific miRNA expression signature characterizing the metastatic phenotype of solid tumors, performed a miRNA microarray analysis on 43 paired primary tumors (ten colon, ten bladder, 13 breast, and ten lung cancers) and one of their related metastatic lymph nodes[@B37]. miR-125b was found to be among the specific miRNAs that may be directly involved in cancer metastasis and that it may represent a novel diagnostic tool in the characterization of metastatic cancer gene. A recent study demonstrates the implication of miR-125b in predicting clinical outcome in breast cancer patients [@B38]. The authors found that miR-125b was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients. In addition, breast cancers with high miR-125b expression prior to chemotherapy had higher percentage of proliferating cells and lower percentage of apoptotic cells in the corresponding surgical specimens obtained after neo-adjuvant chemotherapy, suggesting that miR-125b expression in breast cancers was reversely correlated with apoptosis and proliferation inhibition induced by chemotherapy. This finding has important implications in the development of targeted therapeutics for overcoming chemotherapeutic resistance in novel anti-cancer strategies. Although the evidence supporting the important implication of miR-125 in breast cancer biology has been generated using FBC, the miR-125b behavior observed in the present study has also been found in an earlier study on MBC [@B13], suggesting a similar role for hsa-miR-125b in this pathology, but validation studies are in need for further corroboration.

The differential expression of one miRNA was determined to be correlated with some clinicopathological characteristics of the male breast tumors included in the present study. The expression of miR-125b was significantly correlated with tumor size, feature that has been recognized as a poor prognosis indicator [@B39]. Expression of miR-125b was significantly lower in tumors equal or larger than 2 cm when compare with tumors smaller than 2 cm, suggesting that its down-regulation may be implicated in mechanisms leading to more aggressive tumors. The behavior (up or down-regulation) of each of these miRNAs was consistent in all the samples, which posse several characteristics previously describe in other MBC cohorts. Among these, our cohort presented a high rate of ER and PR positivity and a low rate of Her-2 amplification, three features that distinguish very well between female and male breast carcinomas [@B39].

Overall, our report further supports previous studies about the existence of a tumor-specific miRNA expression signature and contributes to the understanding of miRNA expression patterns and their relationship to carcinogenesis in MBC. Also, our results are consistent with previous data from similar studies regarding miRNA profiling in MBC demonstrating the existence of a miRNA expression signature for this pathology when compare with normal epithelia and with FBC miRNA profiles. Moving forward, large series studies would need to be conducted to address and evaluate the specific role the miRNAs found in the present study potentially have in the biology of MBC, particularly its relationship with prognostic tumor characteristics.

Conclusions
===========

In the present study, we present a comprehensive profiling of 800 miRNA in MBC. Our results further support the hypothesis that MBC have a different miRNA expression profile in comparison with normal mammary tissue and with that reported for FBC. In agreement with previous reports, high grade MBC tumors in our group were mostly ER and PR positive, one of the major differences between male and female breast cancer.

The identification of miRNAs as potential markers of poor prognosis may provide insights into the understanding of these aggressive malignant tumors and may prove to be useful as diagnostic and prognostic tools as well as have a potential roll in the development of new therapeutic approaches. Larger sample studies are required to confirm the results presented in this report and to correlate them with clinical outcome in patients with MBC.

![**Differentially expressed miRNAs between normal epithelium and tumor tissue from male breast cancer patients.** Unsupervised hierarchical clustering of the miRNA expression data showed clear separation between normal and tumor mammary tissue, indicating a cancer-specific expression pattern of a number of miRNAs in our MBC samples.](jcav09p0450g001){#F1}

![**Quantitative real-time PCR validation of microRNA expression profile results on male breast cancer.** Relative expression of microRNAs in male breast cancer compared with normal tissue by real-time PCR in profiling (A) and independent (B) cohorts. miR-200a, miR-30a and miR-183 were over-expressed in cancer samples, whereas miR-125b, miR-145 and miR-1253 were under-expressed. Asterisk, *p* values less than 0.05; error bars, standard deviation.](jcav09p0450g002){#F2}

###### 

Clinicopathological features of male breast cancer patients.

  Characteristics                Number (%)
  ------------------------------ ------------
  **Age in years**               
  Median                         63
  Range                          36-89
  **Histology**                  
  IDC                            29 (69%)
  DCIS                           4 (9.5%)
  IPC                            3 (7.1%)
  PCIS                           4 (9.5%)
  MuC                            1 (2.4%)
  **Grade**                      
  Low                            5 (11.9%)
  Moderate                       15 (35.7%)
  High                           11 (26.2%)
  Unknown                        11 (26.2%)
  **Tumor size**                 
  \<2 cm                         16 (38%)
  ≥2 cm                          18 (43%)
  Unknown                        8 (19%)
  **Lymph node metastasis**      
  Positive                       21 (50%)
  Negative                       9 (21.4%)
  Unknown                        12 (28.6%)
  **Hormone receptors status**   
  ER-positive                    25 (59.5%)
  ER-negative                    3 (7.1%)
  Unknown                        14 (33.3%)
  PR-positive                    24 (57.1%)
  PR-negative                    4 (9.5%)
  Unknown                        14 (33.3%)
  Her-2/neu-positive             6 (21%)
  Her-2/neu-negative             16 (38.1%)
  Unknown                        18 (42.8%)

IDC: Infiltrating Ductal Carcinoma; DCIS: Ductal Carcinoma *In Situ*; IPC: Infiltrating Papillary Carcinoma; PCIS: Papillary Carcinoma *In Situ*; MuC: Mucinous Carcinoma

###### 

MicroRNAs differentially expressed in male breast cancer samples versus normal epithelium

  MicroRNA                            Tumor (normalized)   Normal (normalized)   Fold change   *p*-value   Reported expression in FMC^1^
  ----------------------------------- -------------------- --------------------- ------------- ----------- -------------------------------
  **hsa-miR-200a-3p**                 511                  78                    6.57          0.0052      Up-regulated
  **hsa-miR-30a-5p**                  767                  118                   6.53          0.0160      Up-regulated
  **hsa-miR-29b-3p**                  895                  143                   6.25          0.0101      Up-regulated
  **hsa-miR-222-3p**                  1471                 307                   4.79          0.0585      Down-regulated
  **hsa-miR-141-3p**                  385                  84                    4.60          0.0059      Up-regulated
  **hsa-miR-342-3p**                  7185                 1586                  4.53          0.0339      Up-regulated
  **hsa-miR-135b-5p**                 64                   14                    4.50          0.2240      Down-regulated
  **hsa-miR-29c-3p**                  338                  80                    4.21          0.0281      Up-regulated
  **hsa-miR-183-5p**                  105                  25                    4.13          0.0273      Up-regulated
  **hsa-miR-135a-5p**                 691                  186                   3.71          0.2496      Up-regulated
  **hsa-miR-191-5p**                  1829                 555                   3.30          0.0005      Up-regulated
  **hsa-miR-182-5p**                  45                   14                    3.25          0.0463      Up-regulated
  **hsa-miR-30d-5p**                  580                  181                   3.20          0.0056      Up-regulated
  **hsa-miR-1180**                    152                  48                    3.15          0.0024      Down-regulated
  **hsa-miR-503**                     53                   17                    3.12          0.0431      Down-regulated
  **hsa-miR-200b-3p**                 430                  138                   3.11          0.0185      Up-regulated
  **hsa-miR-15a-5p**                  441                  144                   3.06          0.0002      Up-regulated
  **hsa-miR-582-5p**                  46                   15                    2.96          0.2454      No Reports found
  **hsa-miR-200c-3p**                 1129                 398                   2.84          0.0005      No Reports found
  **hsa-miR-9-5p**                    38                   13                    2.83          0.0510      Down-regulated
  **hsa-miR-34a-5p**                  258                  92                    2.80          0.0465      Down-regulated
  **hsa-miR-106a-5p+hsa-miR-17-5p**   269                  97                    2.76          0.1426      Up-regulated
  **hsa-miR-28-5p**                   122                  45                    2.70          0.0994      No Reports found
  **hsa-miR-4286**                    3509                 1344                  2.61          0.2325      No Reports found
  **hsa-miR-361-3p**                  93                   36                    2.58          0.0148      No Reports found
  **hsa-miR-362-5p**                  40                   15                    2.58          0.0237      Down-regulated
  **hsa-miR-181c-5p**                 64                   25                    2.56          0.0060      Down-regulated
  **hsa-miR-324-5p**                  90                   36                    2.52          0.0463      No Reports found
  **hsa-miR-25-3p**                   1409                 561                   2.51          0.0081      Down-regulated
  **hsa-miR-125a-5p**                 668                  267                   2.50          0.0238      Down-regulated
  **hsa-miR-93-5p**                   668                  272                   2.46          0.0063      Up-regulated
  **hsa-miR-106b-5p**                 146                  59                    2.46          0.0063      Up-regulated
  **hsa-miR-148a-3p**                 835                  339                   2.46          0.0642      No Reports found
  **hsa-miR-660-5p**                  48                   20                    2.41          0.0472      No Reports found
  **hsa-miR-424-5p**                  79                   33                    2.40          0.2037      Down-regulated
  **hsa-miR-425-5p**                  117                  50                    2.36          0.0056      Up-regulated
  **hsa-miR-429**                     70                   30                    2.34          0.0251      Up-regulated
  **hsa-miR-1260b**                   38                   17                    2.29          0.1265      No Reports found
  **hsa-miR-194-5p**                  78                   35                    2.25          0.0205      Down-regulated
  **hsa-miR-96-5p**                   37                   17                    2.23          0.0290      Up-regulated
  **hsa-miR-296-5p**                  78                   35                    2.23          0.0749      Down-regulated
  **hsa-miR-338-3p**                  87                   39                    2.23          0.2052      No Reports found
  **hsa-miR-331-3p**                  82                   38                    2.17          0.0396      Up-regulated
  **hsa-miR-629-5p**                  43                   20                    2.15          0.1488      Up-regulated
  **hsa-miR-1827**                    65                   31                    2.14          0.0860      No Reports found
  **hsa-miR-148b-3p**                 237                  111                   2.13          0.0013      Up-regulated
  **hsa-miR-15b-5p**                  801                  386                   2.08          0.0032      Up-regulated
  **hsa-miR-34c-5p**                  32                   16                    2.08          0.0817      Up-regulated
  **hsa-miR-221-3p**                  337                  164                   2.05          0.4990      Up-regulated
  **hsa-miR-199b-5p**                 164                  342                   -2.08         0.2868      Down-regulated
  **hsa-miR-1915-3p**                 34                   72                    -2.10         0.0649      Down-regulated
  **hsa-miR-199a-5p**                 169                  367                   -2.17         0.3680      Down-regulated
  **hsa-miR-1283**                    69                   165                   -2.40         0.3898      No Reports found
  **hsa-miR-320e**                    133                  343                   -2.59         0.4138      Down-regulated
  **hsa-miR-99a-5p**                  182                  508                   -2.79         0.2010      Down-regulated
  **hsa-miR-27b-3p**                  139                  392                   -2.82         0.1810      No Reports found
  **hsa-miR-601**                     46                   141                   -3.06         0.4475      Down-regulated
  **hsa-miR-579**                     58                   178                   -3.08         0.1265      No Reports found
  **hsa-miR-2116-5p**                 30                   95                    -3.20         0.3402      No Reports found
  **hsa-miR-155-5p**                  64                   209                   -3.27         0.0925      Up-regulated
  **hsa-miR-548aa**                   130                  431                   -3.32         0.1340      No Reports found
  **hsa-miR-23b-3p**                  167                  566                   -3.39         0.0834      No Reports found
  **hsa-miR-1246**                    374                  1401                  -3.75         0.1105      Down-regulated
  **hsa-miR-100-5p**                  79                   301                   -3.81         0.1118      Down-regulated
  **hsa-miR-125b-5p**                 1359                 5610                  -4.13         0.1087      Down-regulated
  **hsa-miR-4516**                    114                  497                   -4.38         0.3296      No Reports found
  **hsa-miR-143-3p**                  296                  1502                  -5.07         0.1961      Down-regulated
  **hsa-miR-214-3p**                  51                   296                   -5.85         0.1025      Down-regulated
  **hsa-miR-575**                     135                  844                   -6.25         0.4096      Down-regulated
  **hsa-miR-548ai**                   37                   243                   -6.49         0.2672      No Reports found
  **hsa-miR-203**                     43                   366                   -8.47         0.4531      Up-regulated
  **hsa-miR-630**                     77                   704                   -9.13         0.3829      Down-regulated
  **hsa-miR-145-5p**                  326                  4174                  -12.80        0.2319      Down-regulated
  **hsa-miR-1253**                    6                    106                   -18.86        0.1520      No Reports found

^1^References[@B23], [@B25], [@B28]

###### 

Correlation between clinicopathological features and miRNA expression

                 Median Expression                     
  -------------- ------------------- ----------------- -----------
                 **Tumor size**                        
                 \<2 cm              ≥2 cm             *P*-value
  hsa-miR-125b   2212.9              949.0             0.03
                                     **Tumor grade**   
                 High                Moderate          
  hsa-miR-200a   176.91              537.952           0.04
  hsa-miR-30a    57.37               943.958           0.02

P-values of \<0.05 were considered significant

[^1]: Competing Interests: The authors have declared that no competing interest exists.
